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Pharmacy Compounding Task Force
The Iowa Board of Pharmacy and the Iowa Pharmacy As-
sociation have established a new task force to review Iowa laws 
and rules pertaining to pharmacy compounding, the licensing 
and regulation of nonresident pharmacies, and drug wholesalers. 
The following individuals have agreed to participate: DeeAnn 
Wedemeyer-Oleson, Lucinda Harms, Gayle Mayer, Alisha 
Eggers, Jack Kampf, Jim Ponto, Ron Hartman, Nic Mastascusa, 
Cindy Marek, Sue Hoffman, Tammy Sharp-Becker, Karmen 
Jorgenson, Manda Johnson, James Van Winkle, Karen Merrill, 
Ken Saunders, Ed Maier, and Sharon Meyer. The task force held 
its first meeting on November 12, 2013. It will make recom-
mendations to the Board sometime during the first half of 2014.
Board Member Remembered
Public Member Margaret “Peggy” 
Boyle Whitworth of Cedar Rapids, IA, 
passed away on October 25, 2013. She 
retired from the Board on April 30, 2013. 
She served six years on the Board, begin-
ning on May 1, 2007. As a public member, 
Peggy was a champion for consumers and 
patients. She worked hard to learn about 
the practice of pharmacy and enjoyed public hearings. Peggy 
was the director of Brucemore, a property of the National Trust 
for Historic Preservation located in Cedar Rapids, for 26 years, 
from 1981 to 2007. In addition to her service on the Board, Peggy 
served on numerous other boards across the state, including the 
Iowa Public Television Foundation Board, the Iowa Historical 
Foundation, and the Cedar Rapids Symphony Orchestra. She 
was a tireless advocate for the arts. Peggy’s brother, Tim Boyle, 
extolled her ability to create change. “While Peggy was small 
in stature, she cast a long and vivid shadow across the commu-
nity in a lot of ways,” he said. “She always tried to comfort the 
disturbed and disturb the comfortable.”
New Board Compliance Officer
Congratulations to pharmacist Andrew R. 
Funk who began working for the Board as 
a compliance officer on November 22, 2013. 
Andrew graduated from Roseman Univer-
sity of Health Sciences in Henderson, NV, 
in May 2004. Most recently, he served as the 
pharmacist-in-charge of Medicap Pharmacy 
in Grimes, IA, from 2006 to 2013. He worked 
for Walgreens in the Des Moines, IA, area from 2005 to 2006. 
The Board and staff welcome Andrew and look forward to 
working with him.
Rules Hearing on December 17, 2013
The Board will hold a public hearing on a proposed rule for 
drug product selection, generic substitution, and branded gener-
ics at 1 PM on Tuesday, December 17, 2013, at the Board office 
in Des Moines. Please contact the Board office in advance of 
the meeting if you plan to attend and provide comments. Space 
is limited and the hearing will be moved to another location if 
necessary. The proposed rule provides as follows:
657 Iowa Administrative Code §6.11 Drug product 
selection. 
Except as provided herein, a pharmacist may exercise 
professional judgment in the economic interest of a patient 
by selecting a drug product with the same generic name 
and demonstrated bioavailability as the drug prescribed 
for dispensing and sale to the patient. If the pharmacist 
exercises drug product selection, the pharmacist shall 
inform the patient of the substitution, the reason for the 
substitution, and any savings realized by the patient as a 
result of the substitution.
6.11(1) Substitution prohibited. A pharmacist shall not 
exercise drug product selection described herein if either 
of the following is true:
a. The prescriber specifically indicates, in any manner, 
that no drug product selection shall be made or that 
only a specified drug product may be dispensed. Pre-
scriber directions prohibiting substitution may include, 
but are not limited to, the following:
(1) Manually signing a prescription on a line that 
indicates substitution is not authorized.
(2) Checking a box on a prescription that indicates 
substitution is not authorized.
(3) Specifically indicating on the face of the prescrip-
tion that no substitution is authorized.
(4) Including the phrase “brand name necessary,” 
“dispense as written,” or “DAW” on the face of 
the prescription. 
(5) Indicating in text on the prescription that only a 
specific product or a specific manufacturer’s prod-
uct may be dispensed. 
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revealed significantly lower adoption in independent pharmacies 
(11.5%) compared to chain pharmacies (62.6%). 
According to a survey conducted by ISMP in 2009, the most 
frequently reported reasons for implementing barcode scanning for 
product verification included a desire to improve the accuracy and 
safety of the dispensing process, the ease with which the technology 
fits with pharmacy workflow, improvement of staff efficiency and 
inventory control, and a belief that the technology was necessary to 
stay in business. The most common reasons for not implementing 
barcode scanning for product verification, other than cost, included 
uncertainty regarding the “right” vendor product, satisfaction with the 
current system (without barcode product verification), and perceptions 
that the technology would reduce staff efficiency.
ISMP has developed a tool, Assessing Barcode Verification System 
Readiness in Community Pharmacies, to help address the reasons 
why barcode scanning has not been implemented and to facilitate 
the adoption of this technology in an estimated 27,327 community 
pharmacies that do not currently utilize it for product verification. 
Given the resource commitment to purchase barcoding systems 
and the potential for technology to have a profound effect upon the 
work environment, this tool will help community pharmacy managers 
and owners better understand the issues related to barcode product 
verification systems. It will also help managers assess the pharmacy’s 
readiness for the technology, prepare for the selection of a system, 
and implement the technology effectively. 
Barcode scanning to verify prescription products prior to dispens-
ing improves the safety and quality of pharmacy care provided to 
patients and increases efficiency during the provision of pharmacy 
services. Although technology should not be seen as a panacea, it can 
be a useful tool when used appropriately and combined with other 
patient safety strategies.3 Does your pharmacy use barcode technol-
ogy for product verification? If not, please access this free tool, at 
www.ismp.org/AHRQ/Default.asp?link=sa.
1Cochran GL, Jones KJ, Brockman J, Skinner A, et al. “Errors prevented by 
and associated with barcode medication systems.” Joint Comm J Qual Pt 
Safety. 2007;33(5):293-301. 
Ukens C. “New study sheds light on medication errors.” Drug Topics. 
2002;146(21):33.
2Skrepnek GH, Armstrong EP, Malone DC, Abarca J, et al. “Workload and 
availability of technology in metropolitan community pharmacies.” J Amer 
Pham Assoc. 2006; 46(2):154-160.
3American Hospital Association, Health Research and Educational Trust, 
Institute for Safe Medication Practices. “Pathways for medication safety: 
assessing bedside bar-coding readiness.” 2002. Accessed on October 15, 
2010 at: www.ismp.org/selfassessments/PathwaySection3.pdf.
ISMP Launches Medication Safety Alert! 
Newsletter Tailored for LTCFs 
ISMP has launched a new ISMP Medication Safety Alert! publica-
tion, Long-Term Care Advise-ERR, as a means to provide medication 
error prevention information tailored to assist staff and providers in 
long-term care facilities (LTCFs). 
With ISMP Medication Safety Alert! publications making a signifi-
cant impact on preventing medication errors, ISMP is now providing 
this new resource tailored to LTCFs. ISMP notes that medication er-
rors reported to ISMP Medication Errors Reporting Program include 
reports from LTCFs. More information and a link to subscribe to this 
new publication are available in the Newsletters section of the ISMP 
Web site at www.ismp.org/newsletters/longtermcare.
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Enteric-Coated Aspirin Recalled for Potential 
Acetaminophen Mix-Up
In June 2013, Advance Pharmaceutical Inc initiated a voluntary 
recall of Rugby Laboratories label enteric-coated aspirin tablets, 81 
mg (Lot 13A026; expiration date: January 2015) due to a complaint 
that a bottle labeled with this product name actually contained acet-
aminophen 500 mg tablets. This over-the-counter (OTC) product is 
packaged in bottles of 120 tablets with National Drug Code 0536-
3086-41 and Universal Product Code 3 0536-3086-41 9. The affected 
lot was distributed nationwide by Rugby Laboratories to wholesal-
ers and retailers. The manufacturer warns that inadvertently taking 
acetaminophen, 500 mg, instead of enteric coated aspirin, 81 mg, 
according to the directions on the label, can lead to an acetaminophen 
overdose and potential severe liver damage. The manufacturer indi-
cates that consumers who take the dosage as indicated on the defective 
product labeling may be ingesting up to 24,000 mg of acetaminophen, 
which is about six times the maximum recommended daily dose of 
acetaminophen (4,000 mg). 
Consumers who have bottles from the affected lot should stop 
using the product and return it to the pharmacy or store where it 
was purchased and should contact a health care provider if they are 
experiencing any problems that may be related to using the product. 
Food and Drug Administration (FDA) notes that any adverse reac-
tions related to the use of the product should be reported to FDA’s 
MedWatch Program. More information about this recall is available 
on the FDA Web site at www.fda.gov/Safety/Recalls/ucm357909.
Barcoding Technology for Community Pharmacy
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and other practitioners. ISMP 
then makes appropriate contacts with companies and regulators, 
gathers expert opinion about prevention measures, and publishes 
its recommendations. To read about the risk reduction strategies 
that you can put into practice today, subscribe to ISMP Medication 
Safety Alert!® Community/Ambulatory Care Edition by visiting www 
.ismp.org. ISMP is a federally certified patient safety organization, 
providing legal protection and confidentiality for submitted patient 
safety data and error reports. ISMP is also an FDA MedWatch partner. 
Call 1-800/FAIL-SAF(E) to report medication errors to the ISMP 
Medication Errors Reporting Program or report online at www.ismp 
.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, PA 19044. 
Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
Barcoding technology is well-established in industries outside of 
the health care sector and is now being used within health care to 
enhance efficiency and safety, and in pharmaceutical wholesale op-
erations to improve supply chain inventory and efficiency. Numerous 
studies prove the effectiveness and cost benefits of using barcoding 
technology during the drug dispensing process. About 75% of wrong 
drug or wrong dose errors are captured and corrected using barcode 
technology1 and there is sufficient evidence that barcode scanning is 
becoming the standard of practice in pharmacies. 
Although barcoding technology is mature with abundant evidence 
regarding its effectiveness, a 20062 study showed that only half 
(53.5%) of United States community pharmacies utilize a barcode 
scanner for verification/identification of medications. The study also 
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FDA Warns of Rare Skin Reactions in Patients 
Taking Acetaminophen 
FDA has issued a consumer update that warns of rare but serious 
skin reactions that may occur in patients taking acetaminophen. These 
complications include three serious skin reactions: Stevens-Johnson 
Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute gen-
eralized exanthematous pustulosis (AGEP). SJS and TEN can both 
be fatal, and usually require hospitalization. Patients suffering from 
AGEP commonly recover within a few weeks after they stop taking 
the medication that caused the reaction. 
Symptoms of these conditions include skin rashes, blisters, and 
widespread damage to the surface of the skin. Patients taking acet-
aminophen or other compounds that contain acetaminophen should 
be advised to stop taking the medication if they experience such 
symptoms and should consult their health care providers or seek an 
emergency department immediately.
FDA emphasizes that this information should be viewed within 
the context of millions of patients who, over generations, have used 
and benefited from acetaminophen and stresses that severe allergic 
skin reactions are an extremely rare condition. Further, the agency 
notes that many medications can cause allergic reactions, and skin 
allergy warnings have already been added to the drug labels of other 
categories of OTC analgesics including ibuprofen and naproxen. 
“This new information is not intended to worry consumers or 
health care professionals, nor is it meant to encourage them to use 
other medications,” said Sharon Hertz, MD, deputy director of 
FDA’s Division of Anesthesia, Analgesia, and Addiction Products. 
“However, it is extremely important that people recognize and react 
quickly to the initial symptoms of these rare but serious side effects, 
which are potentially fatal.” The full consumer update is available 
on the FDA Web site at www.fda.gov/ForConsumers/Consumer 
Updates/ucm363010.htm.
Reminder to Purchase Drugs Only from 
Licensed Wholesalers, Including VAWD-
Accredited Wholesale Distributors
To ensure that patients are receiving safe, FDA-approved 
medications, pharmacists and other health care providers should 
purchase prescription drugs either directly from the manufacturer 
or from wholesale drug distributors licensed in the US as 
advised by FDA. The agency provides a list of state agencies for 
assistance in verifying licensure at www.fda.gov/Drugs/DrugSafety/
DrugIntegrityandSupplyChainSecurity/ucm281446.htm. 
Another way that pharmacies can be assured of the legitimacy 
of a wholesale distributor is to look for the National Association of 
Boards of Pharmacy® (NABP®) Verified-Accredited Wholesale Dis-
tributors® (VAWD®) Seal. Those wholesale distributors that achieve 
VAWD accreditation are in compliance with state and federal laws 
and NABP’s VAWD criteria. NABP has recently revised the VAWD 
criteria to allow virtual manufacturers and virtual wholesale distribu-
tors – a growing segment of the pharmaceutical wholesale industry 
– to qualify for VAWD, as well as to implement other changes aimed 
to help to ensure that the drug supply chain remains secure.
The revised VAWD criteria responds to changing business models 
and helps safeguard drugs in distribution at a time when there is an 
increased risk of counterfeit and substandard drugs entering the legiti-
mate US drug supply chain. In particular, the criteria have been revised 
to provide stronger assurance that drugs diverted from pharmacies and 
unlawful sources are prevented from entering into the supply chain. 
For a listing of VAWD-accredited facilities, please visit www.nabp 
.net/programs/accreditation/vawd.
Voluntary Recall of Unexpired Sterile Products 
After Reports of Adverse Events
FDA has announced a voluntary recall of all lots of unexpired 
sterile products produced by Specialty Compounding, LLC, in Cedar 
Park, TX. FDA received reports of 15 adverse events at two hospitals 
(Corpus Christi Medical Center Doctors Regional and Corpus Christi 
Medical Center Bay Area) potentially related to the use of these 
sterile products. Affected patients received an intravenous infusion 
of calcium gluconate supplied by the company.
Patients who were administered the injectable drug products are at 
risk of life-threatening infections. The recall applies to all unexpired 
sterile compounded medications dispensed by the company, including 
all strengths and dosage forms. Recalled products were distributed 
directly to hospitals and physicians’ offices in Texas, and to patients 
located nationwide (with the exception of North Carolina). No calcium 
gluconate was shipped outside the state of Texas. Health care providers 
and patients should stop using all recalled products and return them 
to Specialty Compounding. 
Veterinarians Not Eligible for NPIs, CMS Clarifies 
Centers for Medicare and Medicaid Services (CMS) has become 
aware of cases in which veterinarians are told, incorrectly, that they 
must provide a National Provider Identifier (NPI) number for pre-
scriptions they have written to be dispensed. The agency has issued 
a clarification, stressing that veterinarians do not meet the regulatory 
definition of “health care provider,” and thus may not obtain NPI 
numbers. The clarification also states that “Any entity that insists 
veterinarians obtain an NPI [is] attempting to require veterinarians 
to obtain NPIs fraudulently.” CMS also notes that “if a veterinarian 
fulfills the definition of ‘health care provider’ in a profession other 
than furnishing veterinary services,” such as if they are also a nurse 
practitioner, “the veterinarian would be eligible for an NPI but would 
select a Nurse Practitioner code (not a Veterinarian code) from the 
Healthcare Provider Taxonomy Code Set when applying for an NPI.”
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
Continuing pharmacy education (CPE) providers who are accredited 
by the Accreditation Council for Pharmacy Education (ACPE) have 
integrated CPE Monitor® into their systems and are requiring pharmacists 
and pharmacy technicians to provide a National Association of Boards 
of Pharmacy® (NABP®) e-Profile ID number and date of birth (MMDD) 
in order to process ACPE-accredited CPE credit.
Visit www.MyCPEmonitor.net to set up your NABP e-Profile and 
register for CPE Monitor and avoid possible delays in your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
National Association of Boards of Pharmacy Foundation, Inc
1600 Feehanville Drive
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b.  The patient or patient’s agent presenting the prescrip-
tion for filling indicates that no substitution shall be 
made. However, if the cost or any part of the cost of 
the prescription will be paid by expenditure of public 
funds authorized under the Iowa Medical Assistance 
Act (Iowa Code Chapter 249A), this paragraph shall 
not apply. 
6.11(2) Prescriber consultation. If a pharmacist is 
unable to provide the specific drug authorized by a pre-
scriber due to unavailability of the product, and if the 
prescriber has indicated that substitution is not authorized 
or has indicated that only a specific product is authorized, 
the pharmacist shall contact the prescriber to explain the 
situation and to discuss alternatives. The pharmacist shall 
note on the prescription record the date of the consultation 
with the prescriber and the results of that consultation. 
The pharmacist shall not dispense a substitute product 
without verbal authorization of the prescriber. The phar-
macist may, however, exercise professional judgment by 
filling a prescription without prescriber authorization if 
the pharmacist is unable to contact the prescriber after 
reasonable effort, the pharmacist determines that failure 
to fill the prescription might result in an interruption of 
therapeutic regimen or create patient suffering, and the 
pharmacist informs the patient at the time of dispensing 
and the prescriber as soon as possible that prescriber 
reauthorization is required. 
6.11(3) Record of substitution. If the pharmacist selects 
a generically equivalent product pursuant to this rule, the 
pharmacist shall note that fact, including the name of 
the manufacturer of the selected product or the national 
drug code of the specific product dispensed, on or with 
the prescription dispensing record.
Board Calendar for 2014
The Board has set the following dates for Board meetings 
in 2014: January 13-14; March 11-12; April 29-30; June 16-17; 
August 26-27; and November 18-19. All meetings will be held 
at the Board office in Des Moines. Please check with the Board 
office at 515/281-5944 for any changes to the meeting schedule.
Board Web Site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and 
protects the public health, safety, and welfare through the ef-
fective regulation of the practice of pharmacy and the licensing 
of pharmacies, pharmacists, and others engaged in the sale, 
delivery, or distribution of prescription drugs and devices. Iowa 
Code §155A.2(1).
Happy Holidays
The Board members wish you a happy and safe holiday 
season.
Pictured left to right: Sharon Meyer, Jim Miller, LaDonna 
Gratias, Ed Maier, Judy Trumpy, Ed McKenna, and Susan Frey
Follow the Board on Facebook and Twitter
Continued from page 1
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/#!/IABoardPharmacy
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